An interventional study of Ultraviolet B lamp in Vitamin D Deficiency and Short Bowel Syndrome, sponsored by University of Nebraska. Completed at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-10-04.
Sponsored by University of Nebraska · Not applicable, Interventional, and Treatment
This is a randomized, controlled, unblinded pilot study for patients with vitamin D deficiency in Intestinal Rehabilitation clinic. These patients are not able to absorb oral vitamin D efficiently and thus have a high prevalence of vitamin D deficiency, leading to low bone density.
The investigators will use FDA approved portable Ultraviolet B lamp for the intervention group, 11 patients will be recruited from October 2013 to end of January 2014 and study period is 12 weeks for each patient. Study completion will be end of April 2014.
Study hypothesis: Ultraviolet B light with a portable ultraviolet device will increase Total 25 hydroxy vitamin D level in Intestinal Rehabilitation Clinic patients.
Vitamin D plays an integral role in bone metabolism and is one of the principal hormonal regulators of calcium and phosphorus absorption in the body. In 2011, the Endocrine Society defined Vitamin D deficiency as a 25 hydroxy vitamin D below 20 ng/ml and vitamin D insufficiency as a 25 hydroxy vitamin D of 21 ng/ml to 29 ng/ml.Without vitamin D, only 10 to 15% of dietary calcium and about 60% of phosphorus is absorbed.
Intestinal Rehabilitation clinic at University of Nebraska Medical Center includes patients with short bowel syndrome, multiple abdominal fistulae, and altered GI motility.
Hypovitaminosis D is associated with increased parathyroid hormone secretion,increased bone turnover, osteoporosis, histological osteomalacia and increased risk of hip and other fractures, and, in its most severe expression,clinical osteomalacia. These patients have been given high doses of both oral vitamin D2 and vitamin D3 supplementation without an improvement in vitamin D status due to poor intestinal absorption . Standardized treatment of vitamin D deficiency in most healthy individuals is achieved by giving vitamin D2 50,000 IU once a week for few weeks and then daily supplementation with lower doses. In the investigators Intestinal rehabilitation clinic, these patients are vitamin D insufficient or deficient while on large replacement doses of vitamin D2/D3 with some taking 200,000 IU daily.
It has been reported that irradiation with Ultraviolet B can be used safely and effectively to treat vitamin D deficiency among vitamin D deficient patients. Exposure of the body in a bathing suit to 1 Minimum Erythemal Dose (MED) of sunlight is equivalent to ingesting about 10,000 IU to 25,000 IU of vitamin D. Thus, exposure of 6% to 10% of the body surface to 1 MED is equivalent to ingesting about 600 to 2500 IU of vitamin D. Although ultraviolet irradiation can be achieved from exposure to sunlight, it is generally available only seasonally and difficult for persons who are too ill to spend much time outdoors. Ultraviolet-Fluorescent lamp (KBD, Inc, Crescent Springs, Kentucky,USA) was designed to use ultraviolet B emitting fluorescent bulbs that have lower heat emission and allows a larger area of skin exposure. The Lamp is equipped with a timer for improved safety. This device is FDA (Food and Drug Administration) approved.
Baseline labs include 25 hydroxy D, intact parathyroid hormone and complete metabolic profile. Patients will receive a 3 minute skin exposure to Ultraviolet B light and if they do not develop a sun burn, they will be randomized to Control or Ultraviolet B light group. Patients will continue their current dose of Vitamin D2/D3 for 12 weeks in both groups.Ultraviolet B light will be administered in 3 different areas on the same day for 5 minutes each, once a week at a distance of 14 inches wearing an UV eye shield. Areas of skin exposure will be based on rule of nine for body surface area which includes back, abdomen, thighs, and arms.
Patients will get blood draws at baseline and 12 weeks to monitor response to Ultraviolet B light. If Ultraviolet B light is able to increase total 25 hydroxy vitamin D level, it can potentially be used at home by these patients after receiving basic training and instructions.
149 studies on the registry are indexed under Short Bowel Syndrome; 25 are open to participants now.
This study's enrollment of 11 is below the median of 20 across 100 interventional studies indexed under Short Bowel Syndrome.
Browse Short Bowel Syndrome studies →University of Nebraska is the lead sponsor of 473 studies on the registry; 66 are open to participants now.
Of its 75 completed or terminated interventional studies of FDA-regulated products, 46 (61%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intervention arm: Patients in the Ultraviolet B lamp group will continue vitamin D2/D3 daily and will receive 3 treatment sessions of Ultraviolet B light once a week for 12 weeks. Patients will receive Ultraviolet B light from Ultraviolet B lamp at a distance of 14 inches for duration of 5 minutes each area while wearing an Ultraviolet eye shield. Areas of skin exposure will include 3 different areas amounting to 27% of body surface area. 9% body surface area will include front of abdomen, lower back, each arm, each leg is 18%, each thigh. Ultraviolet B light sessions will be supervised and conducted by study personnel or Center for Clinical and Translational Research staff. A food questionnaire will be reviewed at each visit to assess dietary intake of calcium. Skin exam will be conducted at the beginning and end of the session.
Device: Ultraviolet B lamp
Patients in control group will continue with their current dose of Vitamin D2/D3 for 12 weeks.Patients will remain on the same steady dose for the duration of the study.These patients will not receive Ultraviolet B light sessions.
Ultraviolet-Fluorescent lamp (KBD, Inc, Crescent Springs, Kentucky, USA) was designed to use Ultraviolet B emitting fluorescent bulbs that have lower heat emission and allows a larger area of skin exposure. The Lamp is equipped with a timer for improved safety. This device is FDA (Food and Drug Administration) approved.
Also known as: Sperti sunlamp "Del Sol"; Sperti, Crescent Springs, Kentucky
25 Hydroxy Vitamin D Levels
Our hypothesis is that Ultraviolet B light with a portable Ultraviolet device will increase Total 25 hydroxy vitamin D level in Intestinal Rehabilitation Clinic patients. We will measure serum level of 25 hydroxy vitamin D at baseline and 12 weeks to monitor the response of Ultraviolet B exposure administered by the portable Ultraviolet B lamp.
Time frame: 12 weeks
Serum Intact Parathyroid Hormone Level
Hypovitaminosis D is associated with increased Parathyroid hormone secretion (inversely related to 25 hydroxy D), increased bone turnover, osteoporosis, histological osteomalacia and increased risk of hip and other fractures, and, in its most severe expression,clinical osteomalacia.
Time frame: 12 weeks
| Milestone | Ultraviolet B Lamp | Control |
|---|---|---|
| Started | 5 | 6 |
| Completed | 3 | 4 |
| Not completed | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 2 |
Our hypothesis is that Ultraviolet B light with a portable Ultraviolet device will increase Total 25 hydroxy vitamin D level in Intestinal Rehabilitation Clinic patients. We will measure serum level of 25 hydroxy vitamin D at baseline and 12 weeks to monitor the response of Ultraviolet B exposure administered by the portable Ultraviolet B lamp.
| ng/mL | Ultraviolet B Lamp | Control |
|---|---|---|
| Week 12 | 26 ± 14 | 14 ± 3 |
| Week 0 | 19 ± 9 | 17 ± 7 |
Hypovitaminosis D is associated with increased Parathyroid hormone secretion (inversely related to 25 hydroxy D), increased bone turnover, osteoporosis, histological osteomalacia and increased risk of hip and other fractures, and, in its most severe expression,clinical osteomalacia.
| pg/ml | Ultraviolet B Lamp | Control |
|---|---|---|
| Week 12 | 62 ± 59 | 70 ± 23 |
| Week 0 | 139 ± 38 | 82 ± 30 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ultraviolet B Lamp | — | 0/3 (0%) | 0/3 (0%) |
| Control | — | 0/4 (0%) | 0/4 (0%) |
Adults age 19 and above with short bowel syndrome recruited from October 2013 to May 2014
| Age, Categorical(Participants) | Ultraviolet B Lamp | Control | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 6 |
| >=65 years | 0 | 1 | 1 |
| Age, Continuous(years) | Ultraviolet B Lamp | Control | Total |
|---|---|---|---|
| Mean | 37 (30 to 58) | 50 (37 to 72) | 47 (30 to 72) |
| Sex: Female, Male(Participants) | Ultraviolet B Lamp | Control | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 1 | 2 | 3 |
| Region of Enrollment(participants) | Ultraviolet B Lamp | Control | Total |
|---|---|---|---|
| United States | 3 | 4 | 7 |
| Baseline vitamin D level(ng/mL) | Ultraviolet B Lamp | Control | Total |
|---|---|---|---|
| Mean | 19 ± 9 | 17 ± 7 | 18 ± 8 |
Plan to share: No
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Nebraska